<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786498</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00069705</org_study_id>
    <nct_id>NCT02786498</nct_id>
  </id_info>
  <brief_title>Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing</brief_title>
  <acronym>Vita-Shock</acronym>
  <official_title>A Blinded Exploratory Randomized Controlled Trial (RCT) to Determine Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to determine the effect of vitamin D3 supplementation on fracture healing at&#xD;
      3 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D supplements are increasingly being recommended to healthy adult fracture patients&#xD;
      without an osteoporotic injury. Although this is a relatively new practice pattern, the basis&#xD;
      for this adjunct therapy is grounded in the high hypovitaminosis D prevalence rates (up to&#xD;
      75%) among healthy adult fracture patients, and the strong biologic rationale for the role of&#xD;
      vitamin D in fracture healing. Briefly, experimental animal studies have demonstrated that&#xD;
      the concentration of vitamin D metabolites is higher at a fracture callus compared to the&#xD;
      uninjured contralateral bone, vitamin D supplementation leads to decreased time to union and&#xD;
      increased callus vascularity, and increases mechanical bone strength compared to controls.&#xD;
      While evidence to confirm that vitamin D supplementation improves fracture healing in&#xD;
      clinical studies does not exist, the pre-clinical data are compelling and worthy of further&#xD;
      investigation.&#xD;
&#xD;
      With modern orthopaedic surgical care, rates of complications following tibia and femoral&#xD;
      shaft fractures can be as high as 15%. Complications, including delayed union, nonunion, or&#xD;
      infection often require secondary surgical procedures and result in profound personal and&#xD;
      societal economic costs. While surgeons continue to seek advances in surgical technique, it&#xD;
      is becoming increasingly obvious that innovations in orthopaedic techniques or implants are&#xD;
      unlikely to eliminate complications. As a result, considerable attention is currently focused&#xD;
      on adjunct biologic therapies, such as vitamin D.&#xD;
&#xD;
      A recent survey of 397 orthopaedic surgeons showed that only 26% routinely prescribe vitamin&#xD;
      D supplementation to adult fracture patients. Of the 93 surgeons who indicated that they&#xD;
      routinely prescribe vitamin D supplementation, 29 different dosing regimens were described&#xD;
      ranging from low daily doses of 400 IU to loading doses of 600,000 IU. This suggests a high&#xD;
      level of clinical uncertainty surrounding the use and optimal dose of vitamin D&#xD;
      supplementation in adult fracture patients. If vitamin D supplementation improves fracture&#xD;
      healing outcomes, then there is a large opportunity to increase its use; however, before&#xD;
      widespread adoption occurs, research is needed to optimize the dosing strategy, establish the&#xD;
      dosing safety in the immobilized fracture healing population, and overcome potential&#xD;
      medication adherence issues among the often marginalized patients that suffer trauma.&#xD;
&#xD;
      The long-term goal of our research program is to conduct a large phase III RCT to determine&#xD;
      which dose of vitamin D3 supplementation optimally improves acute fracture healing outcomes&#xD;
      in healthy adult patients (18-50 years). The current proposed phase II exploratory trial will&#xD;
      perform important preliminary work to test the central hypothesis that vitamin D3 dose and&#xD;
      timing of administration is critical for improving fracture healing at 3 months. This trial&#xD;
      will also inform the feasibility of the large phase III RCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 21, 2016</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Actual">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fracture Healing Will be Assessed Clinically Using Function IndeX for Trauma (FIX-IT)</measure>
    <time_frame>3 months post-injury</time_frame>
    <description>FIX-IT is a standardized measure of weight-bearing and pain in patients with lower extremity fractures, specifically tibia and femur fractures. The FIX-IT score ranges from 0 to 12 points in 2 domains: the ability to bear weight (maximum 6 points) and pain at the fracture site (maximum 6 points) The ability to bear weight is assessed through the single-leg stand and ambulation procedures. Pain is assessed through palpation and stress procedures. The scores in both domains, which are weighted equally, are summed to obtain the final total score; the maximum score of 12 indicates the highest level of function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fracture Healing Will be Assessed Radiographically Using Radiographic Union Score for Tibial Fractures (RUST)</measure>
    <time_frame>3 months post-injury</time_frame>
    <description>Radiographic fracture healing was measured using the Radiographic Union Score for Tibial fractures (RUST), which assesses the presence of bridging callus or a persistent fracture line on each of four cortices. This method evaluates two orthogonal radiographic views; each cortex is attributed points ranging from 1 to 3. A fracture in the immediate postoperative period will receive the minimum score, 4, (1 point for each of the four cortices) and a fully consolidated or healed fracture will be assigned the maximum score, 12 (3 points on each of the four cortices).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fracture Healing Will be Assessed Biochemically Using Serum Levels of the Bone Turnover Marker (BTM) C-terminal Telopeptide of Type I Collagen (CTX)</measure>
    <time_frame>3 months post-injury</time_frame>
    <description>The BTM C-terminal telopeptide of type I collagen (CTX). CTX is a marker of bone resorption. Clinically important changes in the CTX markers are unknown; however, in a previous study of tibia fracture healing, Veitch et al observed concentrations of both bone turnover markers approximately 100% greater than baseline values.43 Given the large changes observed in these bone turnover markers, the same criteria will be applied for identifying a potentially clinically beneficial regimen and remain powered to detect a mean difference of 20% (SD 30%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fracture Healing Will be Assessed Biochemically Using Serum Levels of the Bone Turnover Marker N-terminal Propeptide of Type I Procollagen (P1NP)</measure>
    <time_frame>3 months post-injury</time_frame>
    <description>P1NP is a bone-formation marker and prior research has found that it is highest at 12 weeks after fractures of the tibial shaft and proximal femur.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Level of 25(OH)D</measure>
    <time_frame>Up to 3 months post-injury</time_frame>
    <description>Correlations will be assessed between participants' 25(OH)D levels at enrolment, changes in 25(OH)D levels from enrolment to 3 months, and 25(OH)D levels at 3 months and fracture healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adherence With Vitamin D Supplementation</measure>
    <time_frame>Up to 3 months post-injury</time_frame>
    <description>Will measure adherence with vitamin D supplementation based on participants self report at the 6 week and 3 month visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AE)</measure>
    <time_frame>Up to 12 months post-injury</time_frame>
    <description>A count of the participants who experienced adverse events will measure participant safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Levels of Calcium</measure>
    <time_frame>Up to 3 months post-injury</time_frame>
    <description>Will measure participant safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Levels of Parathyroid Hormone</measure>
    <time_frame>Up to 3 months post-injury</time_frame>
    <description>Helps the body to maintain stable levels of calcium in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants Who Completed Blood Measures</measure>
    <time_frame>Up to 3 months post-injury</time_frame>
    <description>Will measure participants adherence to the blood measures of the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants Who Completed Radiographic Imaging Measures</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Count of participants who completed radiographic imaging measures to determine participant protocol adherence and assists with identifying healing status</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Fracture</condition>
  <arm_group>
    <arm_group_label>High Loading Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Daily Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Daily Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <arm_group_label>High Daily Dose</arm_group_label>
    <arm_group_label>High Loading Dose</arm_group_label>
    <arm_group_label>Low Daily Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>High Daily Dose</arm_group_label>
    <arm_group_label>High Loading Dose</arm_group_label>
    <arm_group_label>Low Daily Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult men or women ages 18-50 years&#xD;
&#xD;
          2. Closed or low grade open (Gustilo type I or II) tibial or femoral shaft fracture&#xD;
&#xD;
          3. Fracture treated with a reamed, locked, intramedullary nail&#xD;
&#xD;
          4. Acute fracture (enrolled within 7 days of injury)&#xD;
&#xD;
          5. Provision of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Osteoporosis&#xD;
&#xD;
          2. Stress fractures&#xD;
&#xD;
          3. Elevated serum calcium (&gt;10.5 mg/dL)&#xD;
&#xD;
          4. Atypical femur fractures as defined by American Society for Bone and Mineral Research&#xD;
             (ASBMR) criteria&#xD;
&#xD;
          5. Pathological fractures secondary to neoplasm or other bone lesion&#xD;
&#xD;
          6. Patients with known or likely undiagnosed disorders of bone metabolism such as Paget's&#xD;
             disease, osteomalacia, osteopetrosis, osteogenesis imperfecta etc.&#xD;
&#xD;
          7. Patients with hyperhomocysteinemia&#xD;
&#xD;
          8. Patients with an allergy to vitamin D or another contraindication to being prescribed&#xD;
             vitamin D&#xD;
&#xD;
          9. Patients currently taking an over the counter multivitamin that contains vitamin D and&#xD;
             are unable or unwilling to discontinue its use for this study&#xD;
&#xD;
         10. Patients who will likely have problems, in the judgment of the investigators, with&#xD;
             maintaining follow-up&#xD;
&#xD;
         11. Pregnancy&#xD;
&#xD;
         12. Patients who are incarcerated&#xD;
&#xD;
         13. Patients who are not expected to survive their injuries&#xD;
&#xD;
         14. Other lower extremity injuries that prevent bilateral full weight-bearing by 6 weeks&#xD;
             post-fracture.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Slobogean, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheila Sprague, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, R Adams Cowley Shock Trauma Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University, Center for Evidence-Based Orthopaedics</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 8E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sprague S, Petrisor B, Scott T, Devji T, Phillips M, Spurr H, Bhandari M, Slobogean GP. What Is the Role of Vitamin D Supplementation in Acute Fracture Patients? A Systematic Review and Meta-Analysis of the Prevalence of Hypovitaminosis D and Supplementation Efficacy. J Orthop Trauma. 2016 Feb;30(2):53-63. doi: 10.1097/BOT.0000000000000455. Review.</citation>
    <PMID>26429406</PMID>
  </reference>
  <reference>
    <citation>Omeroğlu S, Erdoğan D, Omeroğlu H. Effects of single high-dose vitamin D3 on fracture healing. An ultrastructural study in healthy guinea pigs. Arch Orthop Trauma Surg. 1997;116(1-2):37-40.</citation>
    <PMID>9006763</PMID>
  </reference>
  <reference>
    <citation>Jingushi S, Iwaki A, Higuchi O, Azuma Y, Ohta T, Shida JI, Izumi T, Ikenoue T, Sugioka Y, Iwamoto Y. Serum 1alpha,25-dihydroxyvitamin D3 accumulates into the fracture callus during rat femoral fracture healing. Endocrinology. 1998 Apr;139(4):1467-73.</citation>
    <PMID>9528922</PMID>
  </reference>
  <reference>
    <citation>Lidor C, Dekel S, Edelstein S. The metabolism of vitamin D3 during fracture healing in chicks. Endocrinology. 1987 Jan;120(1):389-93.</citation>
    <PMID>3023034</PMID>
  </reference>
  <reference>
    <citation>Lidor C, Dekel S, Hallel T, Edelstein S. Levels of active metabolites of vitamin D3 in the callus of fracture repair in chicks. J Bone Joint Surg Br. 1987 Jan;69(1):132-6.</citation>
    <PMID>3029136</PMID>
  </reference>
  <reference>
    <citation>Omeroğlu H, Ateş Y, Akkuş O, Korkusuz F, Biçimoğlu A, Akkaş N. Biomechanical analysis of the effects of single high-dose vitamin D3 on fracture healing in a healthy rabbit model. Arch Orthop Trauma Surg. 1997;116(5):271-4.</citation>
    <PMID>9177802</PMID>
  </reference>
  <reference>
    <citation>Study to Prospectively Evaluate Reamed Intramedullary Nails in Patients with Tibial Fractures Investigators, Bhandari M, Guyatt G, Tornetta P 3rd, Schemitsch EH, Swiontkowski M, Sanders D, Walter SD. Randomized trial of reamed and unreamed intramedullary nailing of tibial shaft fractures. J Bone Joint Surg Am. 2008 Dec;90(12):2567-78. doi: 10.2106/JBJS.G.01694.</citation>
    <PMID>19047701</PMID>
  </reference>
  <reference>
    <citation>Duan X, Al-Qwbani M, Zeng Y, Zhang W, Xiang Z. Intramedullary nailing for tibial shaft fractures in adults. Cochrane Database Syst Rev. 2012 Jan 18;1:CD008241. doi: 10.1002/14651858.CD008241.pub2. Review.</citation>
    <PMID>22258982</PMID>
  </reference>
  <reference>
    <citation>Bhandari M, Guyatt GH, Tong D, Adili A, Shaughnessy SG. Reamed versus nonreamed intramedullary nailing of lower extremity long bone fractures: a systematic overview and meta-analysis. J Orthop Trauma. 2000 Jan;14(1):2-9.</citation>
    <PMID>10630795</PMID>
  </reference>
  <reference>
    <citation>Bonafede M, Espindle D, Bower AG. The direct and indirect costs of long bone fractures in a working age US population. J Med Econ. 2013;16(1):169-78. doi: 10.3111/13696998.2012.737391. Epub 2012 Oct 22.</citation>
    <PMID>23035626</PMID>
  </reference>
  <reference>
    <citation>Antonova E, Le TK, Burge R, Mershon J. Tibia shaft fractures: costly burden of nonunions. BMC Musculoskelet Disord. 2013 Jan 26;14:42. doi: 10.1186/1471-2474-14-42.</citation>
    <PMID>23351958</PMID>
  </reference>
  <reference>
    <citation>Kanakaris NK, Giannoudis PV. The health economics of the treatment of long-bone non-unions. Injury. 2007 May;38 Suppl 2:S77-84. Review. Erratum in: Injury. 2007 Oct;38(10):1224.</citation>
    <PMID>17920421</PMID>
  </reference>
  <reference>
    <citation>Bhandari M, Schemitsch EH. Stimulation of fracture healing: osteobiologics, bone stimulators, and beyond. J Orthop Trauma. 2010 Mar;24 Suppl 1:S1. doi: 10.1097/BOT.0b013e3181d2d683.</citation>
    <PMID>20182228</PMID>
  </reference>
  <reference>
    <citation>Marsell R, Einhorn TA. Emerging bone healing therapies. J Orthop Trauma. 2010 Mar;24 Suppl 1:S4-8. doi: 10.1097/BOT.0b013e3181ca3fab.</citation>
    <PMID>20182234</PMID>
  </reference>
  <reference>
    <citation>Schoelles K, Snyder D, Kaczmarek J, Kuserk E, Erinoff E, Turkelson C, Coates V. The Role of Bone Growth Stimulating Devices and Orthobiologics in Healing Nonunion Fractures [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Sep 21. Available from http://www.ncbi.nlm.nih.gov/books/NBK285118/</citation>
    <PMID>25879121</PMID>
  </reference>
  <reference>
    <citation>Veitch SW, Findlay SC, Hamer AJ, Blumsohn A, Eastell R, Ingle BM. Changes in bone mass and bone turnover following tibial shaft fracture. Osteoporos Int. 2006;17(3):364-72. Epub 2005 Dec 15.</citation>
    <PMID>16362144</PMID>
  </reference>
  <reference>
    <citation>Højsager FD, Rand MS, Pedersen SB, Nissen N, Jørgensen NR. Fracture-induced changes in biomarkers CTX, PINP, OC, and BAP-a systematic review. Osteoporos Int. 2019 Dec;30(12):2381-2389. doi: 10.1007/s00198-019-05132-1. Epub 2019 Aug 24.</citation>
    <PMID>31446441</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <results_first_submitted>December 3, 2020</results_first_submitted>
  <results_first_submitted_qc>March 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 1, 2021</results_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Gerard Slobogean</investigator_full_name>
    <investigator_title>Associate Professor of Orthopaedics</investigator_title>
  </responsible_party>
  <keyword>Tibial Shaft</keyword>
  <keyword>Tibia</keyword>
  <keyword>Femoral Shaft</keyword>
  <keyword>Femur</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Fracture Healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02786498/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Loading Dose</title>
          <description>150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
        </group>
        <group group_id="P2">
          <title>High Daily Dose</title>
          <description>Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
        </group>
        <group group_id="P3">
          <title>Low Daily Dose</title>
          <description>Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
        </group>
        <group group_id="P4">
          <title>Control Group</title>
          <description>Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Loading Dose</title>
          <description>150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
        </group>
        <group group_id="B2">
          <title>High Daily Dose</title>
          <description>Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Low Daily Dose</title>
          <description>Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
        </group>
        <group group_id="B4">
          <title>Control Group</title>
          <description>Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.4" spread="8.1"/>
                    <measurement group_id="B2" value="28.8" spread="7.3"/>
                    <measurement group_id="B3" value="31.1" spread="9.8"/>
                    <measurement group_id="B4" value="31.3" spread="7.9"/>
                    <measurement group_id="B5" value="29.65" spread="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Current Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Previous Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fractured bone (Tibia)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Association for the Study of Internal fixation /Orthopaedic Trauma AssociationClassification (AO/OTA</title>
          <description>This system provides the clinician with standardized definitions so the verbal fracture description is precise and consistent from bone to bone and fracture to fracture. The system also provides a mechanism to convert the verbal description into an alphanumeric code to allow for data storage and future recall.&#xD;
The Numeric value indicates the bone while the values &quot;A, B, C&quot; indicate the type and severity of the fracture where A is a simple fracture and C is a complex fracture.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>AO/OTA Class 32.A</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>AO/OTA Class 32.B</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>AO/OTA Class 32.C</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>AO/OTA Class 42.A</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>AO/OTA Class 42.B</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>AO/OTA Class 42.C</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vitamin D3 deficient (25(OH)D Serum Levels ,20 ng/mL)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fracture Healing Will be Assessed Clinically Using Function IndeX for Trauma (FIX-IT)</title>
        <description>FIX-IT is a standardized measure of weight-bearing and pain in patients with lower extremity fractures, specifically tibia and femur fractures. The FIX-IT score ranges from 0 to 12 points in 2 domains: the ability to bear weight (maximum 6 points) and pain at the fracture site (maximum 6 points) The ability to bear weight is assessed through the single-leg stand and ambulation procedures. Pain is assessed through palpation and stress procedures. The scores in both domains, which are weighted equally, are summed to obtain the final total score; the maximum score of 12 indicates the highest level of function.</description>
        <time_frame>3 months post-injury</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Loading Dose</title>
            <description>150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>High Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O3">
            <title>Low Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fracture Healing Will be Assessed Clinically Using Function IndeX for Trauma (FIX-IT)</title>
          <description>FIX-IT is a standardized measure of weight-bearing and pain in patients with lower extremity fractures, specifically tibia and femur fractures. The FIX-IT score ranges from 0 to 12 points in 2 domains: the ability to bear weight (maximum 6 points) and pain at the fracture site (maximum 6 points) The ability to bear weight is assessed through the single-leg stand and ambulation procedures. Pain is assessed through palpation and stress procedures. The scores in both domains, which are weighted equally, are summed to obtain the final total score; the maximum score of 12 indicates the highest level of function.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="2.5"/>
                    <measurement group_id="O2" value="9.7" spread="2.8"/>
                    <measurement group_id="O3" value="9.3" spread="3.3"/>
                    <measurement group_id="O4" value="9.0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fracture Healing Will be Assessed Radiographically Using Radiographic Union Score for Tibial Fractures (RUST)</title>
        <description>Radiographic fracture healing was measured using the Radiographic Union Score for Tibial fractures (RUST), which assesses the presence of bridging callus or a persistent fracture line on each of four cortices. This method evaluates two orthogonal radiographic views; each cortex is attributed points ranging from 1 to 3. A fracture in the immediate postoperative period will receive the minimum score, 4, (1 point for each of the four cortices) and a fully consolidated or healed fracture will be assigned the maximum score, 12 (3 points on each of the four cortices).</description>
        <time_frame>3 months post-injury</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Loading Dose</title>
            <description>150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>High Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O3">
            <title>Low Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fracture Healing Will be Assessed Radiographically Using Radiographic Union Score for Tibial Fractures (RUST)</title>
          <description>Radiographic fracture healing was measured using the Radiographic Union Score for Tibial fractures (RUST), which assesses the presence of bridging callus or a persistent fracture line on each of four cortices. This method evaluates two orthogonal radiographic views; each cortex is attributed points ranging from 1 to 3. A fracture in the immediate postoperative period will receive the minimum score, 4, (1 point for each of the four cortices) and a fully consolidated or healed fracture will be assigned the maximum score, 12 (3 points on each of the four cortices).</description>
          <units>Score on a scale 4-12</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="2.8"/>
                    <measurement group_id="O2" value="11.3" spread="2.9"/>
                    <measurement group_id="O3" value="11.0" spread="3.0"/>
                    <measurement group_id="O4" value="10.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fracture Healing Will be Assessed Biochemically Using Serum Levels of the Bone Turnover Marker (BTM) C-terminal Telopeptide of Type I Collagen (CTX)</title>
        <description>The BTM C-terminal telopeptide of type I collagen (CTX). CTX is a marker of bone resorption. Clinically important changes in the CTX markers are unknown; however, in a previous study of tibia fracture healing, Veitch et al observed concentrations of both bone turnover markers approximately 100% greater than baseline values.43 Given the large changes observed in these bone turnover markers, the same criteria will be applied for identifying a potentially clinically beneficial regimen and remain powered to detect a mean difference of 20% (SD 30%).</description>
        <time_frame>3 months post-injury</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Loading Dose</title>
            <description>150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>High Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O3">
            <title>Low Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fracture Healing Will be Assessed Biochemically Using Serum Levels of the Bone Turnover Marker (BTM) C-terminal Telopeptide of Type I Collagen (CTX)</title>
          <description>The BTM C-terminal telopeptide of type I collagen (CTX). CTX is a marker of bone resorption. Clinically important changes in the CTX markers are unknown; however, in a previous study of tibia fracture healing, Veitch et al observed concentrations of both bone turnover markers approximately 100% greater than baseline values.43 Given the large changes observed in these bone turnover markers, the same criteria will be applied for identifying a potentially clinically beneficial regimen and remain powered to detect a mean difference of 20% (SD 30%).</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="0.75"/>
                    <measurement group_id="O2" value="0.79" spread="0.93"/>
                    <measurement group_id="O3" value="0.67" spread="0.64"/>
                    <measurement group_id="O4" value="0.78" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fracture Healing Will be Assessed Biochemically Using Serum Levels of the Bone Turnover Marker N-terminal Propeptide of Type I Procollagen (P1NP)</title>
        <description>P1NP is a bone-formation marker and prior research has found that it is highest at 12 weeks after fractures of the tibial shaft and proximal femur.</description>
        <time_frame>3 months post-injury</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Loading Dose</title>
            <description>150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>High Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O3">
            <title>Low Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fracture Healing Will be Assessed Biochemically Using Serum Levels of the Bone Turnover Marker N-terminal Propeptide of Type I Procollagen (P1NP)</title>
          <description>P1NP is a bone-formation marker and prior research has found that it is highest at 12 weeks after fractures of the tibial shaft and proximal femur.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.9" spread="140.1"/>
                    <measurement group_id="O2" value="187.8" spread="129.3"/>
                    <measurement group_id="O3" value="166.7" spread="115.8"/>
                    <measurement group_id="O4" value="140.7" spread="124.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Level of 25(OH)D</title>
        <description>Correlations will be assessed between participants' 25(OH)D levels at enrolment, changes in 25(OH)D levels from enrolment to 3 months, and 25(OH)D levels at 3 months and fracture healing</description>
        <time_frame>Up to 3 months post-injury</time_frame>
        <population>Serum 25(OH)D Concentration by Treatment Group</population>
        <group_list>
          <group group_id="O1">
            <title>High Loading Dose</title>
            <description>150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>High Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O3">
            <title>Low Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Level of 25(OH)D</title>
          <description>Correlations will be assessed between participants' 25(OH)D levels at enrolment, changes in 25(OH)D levels from enrolment to 3 months, and 25(OH)D levels at 3 months and fracture healing</description>
          <population>Serum 25(OH)D Concentration by Treatment Group</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="7.8"/>
                    <measurement group_id="O2" value="20.7" spread="9.6"/>
                    <measurement group_id="O3" value="19.7" spread="7.9"/>
                    <measurement group_id="O4" value="17.3" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" spread="17.8"/>
                    <measurement group_id="O2" value="38.4" spread="18.6"/>
                    <measurement group_id="O3" value="35.5" spread="22.5"/>
                    <measurement group_id="O4" value="26.1" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.9" spread="17.9"/>
                    <measurement group_id="O2" value="28.2" spread="20.7"/>
                    <measurement group_id="O3" value="38.1" spread="19.8"/>
                    <measurement group_id="O4" value="23.1" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adherence With Vitamin D Supplementation</title>
        <description>Will measure adherence with vitamin D supplementation based on participants self report at the 6 week and 3 month visits.</description>
        <time_frame>Up to 3 months post-injury</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Loading Dose</title>
            <description>150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>High Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O3">
            <title>Low Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adherence With Vitamin D Supplementation</title>
          <description>Will measure adherence with vitamin D supplementation based on participants self report at the 6 week and 3 month visits.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AE)</title>
        <description>A count of the participants who experienced adverse events will measure participant safety</description>
        <time_frame>Up to 12 months post-injury</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Loading Dose</title>
            <description>150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>High Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O3">
            <title>Low Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AE)</title>
          <description>A count of the participants who experienced adverse events will measure participant safety</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Levels of Calcium</title>
        <description>Will measure participant safety</description>
        <time_frame>Up to 3 months post-injury</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Loading Dose</title>
            <description>150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>High Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O3">
            <title>Low Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of Calcium</title>
          <description>Will measure participant safety</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="0.6"/>
                    <measurement group_id="O2" value="8.8" spread="0.7"/>
                    <measurement group_id="O3" value="8.3" spread="1.8"/>
                    <measurement group_id="O4" value="9.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="0.3"/>
                    <measurement group_id="O2" value="9.6" spread="0.3"/>
                    <measurement group_id="O3" value="9.6" spread="0.4"/>
                    <measurement group_id="O4" value="9.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="0.3"/>
                    <measurement group_id="O2" value="9.6" spread="0.5"/>
                    <measurement group_id="O3" value="9.7" spread="0.4"/>
                    <measurement group_id="O4" value="9.6" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Levels of Parathyroid Hormone</title>
        <description>Helps the body to maintain stable levels of calcium in the blood</description>
        <time_frame>Up to 3 months post-injury</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Loading Dose</title>
            <description>150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>High Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O3">
            <title>Low Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of Parathyroid Hormone</title>
          <description>Helps the body to maintain stable levels of calcium in the blood</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" spread="39.0"/>
                    <measurement group_id="O2" value="64.7" spread="37.2"/>
                    <measurement group_id="O3" value="67.8" spread="35.1"/>
                    <measurement group_id="O4" value="60.3" spread="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9" spread="47.7"/>
                    <measurement group_id="O2" value="28.8" spread="32.2"/>
                    <measurement group_id="O3" value="68.0" spread="63.2"/>
                    <measurement group_id="O4" value="43.6" spread="47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" spread="39.6"/>
                    <measurement group_id="O2" value="71.0" spread="68.0"/>
                    <measurement group_id="O3" value="63.1" spread="48.1"/>
                    <measurement group_id="O4" value="74.6" spread="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants Who Completed Blood Measures</title>
        <description>Will measure participants adherence to the blood measures of the protocol.</description>
        <time_frame>Up to 3 months post-injury</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Loading Dose</title>
            <description>150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>High Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O3">
            <title>Low Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants Who Completed Blood Measures</title>
          <description>Will measure participants adherence to the blood measures of the protocol.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants Who Completed Radiographic Imaging Measures</title>
        <description>Count of participants who completed radiographic imaging measures to determine participant protocol adherence and assists with identifying healing status</description>
        <time_frame>up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Loading Dose</title>
            <description>150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>High Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O3">
            <title>Low Daily Dose</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants Who Completed Radiographic Imaging Measures</title>
          <description>Count of participants who completed radiographic imaging measures to determine participant protocol adherence and assists with identifying healing status</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months after initial injury</time_frame>
      <desc>An Adverse Event (AE) is any symptom, sign, illness, or experience that develops or worsens in severity during the course of this study.&#xD;
AEs are classified as serious or non-serious.</desc>
      <group_list>
        <group group_id="E1">
          <title>High Loading Dose</title>
          <description>150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
        </group>
        <group group_id="E2">
          <title>High Daily Dose</title>
          <description>Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
        </group>
        <group group_id="E3">
          <title>Low Daily Dose</title>
          <description>Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.&#xD;
Vitamin D3&#xD;
Placebo</description>
        </group>
        <group group_id="E4">
          <title>Control Group</title>
          <description>Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.&#xD;
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Sickle Cell Crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accident/Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cellulitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture Healing Complication</sub_title>
                <description>fracture healing complications will be identified, and will include nonunion, delayed union, hardware failure 33 wound healing problems and infection (superficial and deep as defined by Centers for Disease Control and Prevention (CDC) criteria).</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Non-study Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Retained Foreign Object</sub_title>
                <description>Symptomatic Bullet</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Re-operations for fracture healing complications</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Miscarriage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Recurrent Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Gerard Slobogean</name_or_title>
      <organization>University of Maryland Baltimore, School of Medicine, Department of Orthopaedics</organization>
      <phone>410-28-6280</phone>
      <email>gslobogean@som.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

